treatment paradigm of pain medicines.
We are a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction.
Pain represents one of the largest and most pervasive therapeutic markets in the United States. Current treatments for pain management require difficult tradeoffs between efficacy, safety, tolerability, and risk of addiction. These leave many patients either undertreated or exposed to therapies with significant limitations or addiction potential.
Latigo’s goal is to provide effective, rapid-acting pain relief without the risk of addiction.